Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Caribou Biosciences (CRBU) over the last 6 years, with Dec 2024 value amounting to -$149.1 million.

  • Caribou Biosciences' Income towards Parent Company rose 23.11% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 3.88%. This contributed to the annual value of -$149.1 million for FY2024, which is 46.08% down from last year.
  • Per Caribou Biosciences' latest filing, its Income towards Parent Company stood at -$149.1 million for FY2024, which was down 46.08% from -$102.1 million recorded in FY2023.
  • Caribou Biosciences' 5-year Income towards Parent Company high stood at -$34.3 million for FY2020, and its period low was -$149.1 million during FY2024.
  • Its 3-year average for Income towards Parent Company is -$116.9 million, with a median of -$102.1 million in 2023.
  • Data for Caribou Biosciences' Income towards Parent Company shows a maximum YoY plummeted of 95.07% (in 2021) over the last 5 years.
  • Over the past 5 years, Caribou Biosciences' Income towards Parent Company (Yearly) stood at -$34.3 million in 2020, then crashed by 95.07% to -$66.9 million in 2021, then crashed by 48.56% to -$99.4 million in 2022, then declined by 2.66% to -$102.1 million in 2023, then slumped by 46.08% to -$149.1 million in 2024.